Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 31562043

Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2019 Nov
First author
Bisogno G

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Nov;20(11):1476-1477. doi: 10.1016/S1470-2045(19)30618-7.
    note
    Source null
    related pmid
    31562042
    relationship
    Comment in
  2. citation
    Trends Cancer. 2019 Dec;5(12):756-759. doi: 10.1016/j.trecan.2019.10.004.
    note
    Source null
    related pmid
    31813450
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Jan;21(1):e1. doi: 10.1016/S1470-2045(19)30731-4.
    note
    Source null
    related pmid
    31908295
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Jan;21(1):e2. doi: 10.1016/S1470-2045(19)30784-3.
    note
    Source null
    related pmid
    31908302
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5.
    note
    Source null
    related pmid
    31908304
    relationship
    Comment in

Authors and identifiers

  1. name
    Bisogno G
    type
    Author
  2. name
    De Salvo GL
    type
    Author
  3. name
    Bergeron C
    type
    Author
  4. name
    Gallego Melcón S
    type
    Author
  5. name
    Merks JH
    type
    Author
  6. name
    Kelsey A
    type
    Author
  7. name
    Martelli H
    type
    Author
  8. name
    Minard-Colin V
    type
    Author
  9. name
    Orbach D
    type
    Author
  10. name
    Glosli H
    type
    Author
  11. name
    Chisholm J
    type
    Author
  12. name
    Casanova M
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Bisogno G
    type
    Author
  2. name
    De Salvo GL
    type
    Author
  3. name
    Bergeron C
    type
    Author
  4. name
    Gallego Melcón S
    type
    Author
  5. name
    Merks JH
    type
    Author
  6. name
    Kelsey A
    type
    Author
  7. name
    Martelli H
    type
    Author
  8. name
    Minard-Colin V
    type
    Author
  9. name
    Orbach D
    type
    Author
  10. name
    Glosli H
    type
    Author
  11. name
    Chisholm J
    type
    Author
  12. name
    Casanova M
    type
    Author
bibliography ids
  1. nci-bib-a64bfa269fe6e3f0d8e0bf71
book metadata
content sha256
354f0a66cea3681e76322a337529f5e4078a7125a5d185e5855518967b4f78b5
document type
citation
dois
  1. 10.1016/S1470-2045(19)30617-5
electronic publication date
display
2019 Sep 24
precision
day
year
2019
evidence scope
bibliographic_metadata_only
id
pubmed:31562043
immutable id
pubmed:31562043@354f0a66cea3681e76322a337529f5e4078a7125a5d185e5855518967b4f78b5
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
11
name
The Lancet. Oncology
nlm unique id
100957246
pages
1566-1575
volume
20
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2019 Nov;20(11):1476-1477. doi: 10.1016/S1470-2045(19)30618-7.
    note
    Source null
    related pmid
    31562042
    relationship
    Comment in
  2. citation
    Trends Cancer. 2019 Dec;5(12):756-759. doi: 10.1016/j.trecan.2019.10.004.
    note
    Source null
    related pmid
    31813450
    relationship
    Comment in
  3. citation
    Lancet Oncol. 2020 Jan;21(1):e1. doi: 10.1016/S1470-2045(19)30731-4.
    note
    Source null
    related pmid
    31908295
    relationship
    Comment in
  4. citation
    Lancet Oncol. 2020 Jan;21(1):e2. doi: 10.1016/S1470-2045(19)30784-3.
    note
    Source null
    related pmid
    31908302
    relationship
    Comment in
  5. citation
    Lancet Oncol. 2020 Jan;21(1):e3. doi: 10.1016/S1470-2045(19)30812-5.
    note
    Source null
    related pmid
    31908304
    relationship
    Comment in
outcomes validated
false
pmid
31562043
provenance
batch id
23ffe1e2a9e160b6dca0
provider
NCBI PubMed ESummary
record sha256
43a8bd9dbd737c3d7e8535e02c6865a0585ef7b53b1be9cf80f3d6d92e2d7d69
response sha256
d5cbfde8f87ba85b214c53aaf0e8fa33d70fec48dd4fde7745538180cd7e1841
retrieved at
2026-09-09T23:47:44.690737+00:00
publication date
display
2019 Nov
precision
month
year
2019
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
  5. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/31562043/
title
Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): a multicentre, open-label, randomised, phase 3 trial.

Preserved source evidence · Not medical advice